|
|
|
|
| LEADER |
00000cam a2200000 i 4500 |
| 001 |
EBSCO_ocn926705916 |
| 003 |
OCoLC |
| 005 |
20231017213018.0 |
| 006 |
m o d |
| 007 |
cr ||||||||||| |
| 008 |
150706s2015 nyua ob 001 0 eng |
| 010 |
|
|
|a 2020687197
|
| 040 |
|
|
|a DLC
|b eng
|e rda
|e pn
|c DLC
|d N$T
|d YDXCP
|d OCLCF
|d EBLCP
|d AGLDB
|d VTS
|d AU@
|d STF
|d M8D
|d VLY
|d OCLCO
|d OCLCQ
|
| 020 |
|
|
|a 9781634834728
|q (ebook)
|
| 020 |
|
|
|a 1634834720
|
| 020 |
|
|
|z 1634834712
|q (hbk.)
|
| 020 |
|
|
|z 9781634834711
|q (hbk.)
|
| 029 |
1 |
|
|a AU@
|b 000056997592
|
| 029 |
1 |
|
|a DEBSZ
|b 493169350
|
| 035 |
|
|
|a (OCoLC)926705916
|
| 050 |
0 |
0 |
|a RC280.L8
|
| 072 |
|
7 |
|a HEA
|x 039000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 014000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 022000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 112000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 045000
|2 bisacsh
|
| 082 |
0 |
0 |
|a 616.99/424
|2 23
|
| 049 |
|
|
|a UAMI
|
| 245 |
0 |
0 |
|a Encyclopedia of lung cancer /
|c Andrea Hawkins, editor.
|
| 264 |
|
1 |
|a New York :
|b Nova Biomedical,
|c [2015]
|
| 300 |
|
|
|a 1 online resource
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Cancer etiology, diagnosis, and treatments
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 588 |
0 |
|
|a Print version record.
|
| 505 |
0 |
|
|a ENCYCLOPEDIA OF LUNG CANCER ; ENCYCLOPEDIA OF LUNG CANCER ; Library of Congress Cataloging-in-Publication Data; CONTENTS ; PREFACE ; Chapter 1 THERAPEUTIC ANTIBODIES IN NON-SMALL CELL LUNG CANCER: AN OVERVIEW AND FUTURE DIRECTIONS ; ABSTRACT ; INTRODUCTION ; 1. THERAPEUTIC ANTIBODIES IN CANCER: RATIONALE ; 1.1. Structure of Monoclonal Antibodies (Mab) ; 1.2. History of Therapeutic mAbs ; 1.3. Pharmacodynamic ; 1.3.1. Fab Domain ; 1.3.2. Fc Domain ; 1.3.3. Conjugated or Armed mAbs ; 1.4. Pharmacokinetics of mAbs ; 1.4.1. FcRn Receptor ; 1.4.2. Administration and Absorption
|
| 505 |
8 |
|
|a 1.4.3. Distribution 1.4.4. Metabolism and Elimination ; 1.4.5. Engineered IgG and Their Pharmacokinetics ; 1.4.6. Other Factors Influencing the Pharmacokinetics of mAbs ; 1.5. Immunogenicity and Safety of mAbs ; 1.5.1. Anti-Antibody Response (AAR) ; 1.5.2. Cytokine Release Syndrome (CRS) ; 2. THERAPEUTIC ANTIBODIES IN NON SMALL CELL LUNG CANCER (NSCLC): PRE-CLINICAL AND CLINICAL STUDIES ; 2.1. Anti-VEGF Antibodies ; 2.1.1. Vascular Epidermal Growth Factor (VEGF) and NSCLC ; 2.1.2. Bevacizumab ; 2.1.2.1. Preclinical Studies with Bevacizumab ; 2.1.2.2. Pharmacokinetic
|
| 505 |
8 |
|
|a 2.1.3. Clinical Trials of Bevacizumab Combined with Chemotherapy 2.1.3.1. Phase II Clinical Trial ; 2.1.3.2. Phase II Clinical Trial in Squamous Non Small Cell Lung Cancer ; 2.1.3.3. Phase III Clinical Trials in Non Squamous Non Small Cell Lung Cancer ; 2.1.3.4. Phase IV Clinical Trials in Non Squamous Non Small Cell Lung Cancer ; 2.1.3.5. Bevacizumab As Maintenance Therapy: Current Concepts ; 2.1.3.6. Bevacizumab As Maintenance Therapy: Future Directions; 2.1.4. Clinical Trials of Bevacizumab Combined with Targeted Therapy ; 2.1.4.1. Erlotinib ; 2.1.4.1.1. Phase I and II Trials
|
| 505 |
8 |
|
|a 2.1.4.1.2. Phase III Trial 2.1.4.1.3. Erlotinib and Bevacizumab: Future Directions ; 2.1.4.2. Sunitinib ; 2.1.5. Clinical Trials of Bevacizumab in Elderly Patients ; 2.1.6. Predictive Markers ; 2.1.6.1. Current Concepts ; 2.1.6.2. Future Directions ; 2.1.7. Anti-VEGFR2: Ramucirumab ; 2.1.8. Fab Anti-VEGF: Ranibizumab ; 2.2. Anti-HER Antibodies ; 2.2.1. EGFR and Signaling Pathways ; 2.2.1.1. ERBB1 (EGFR) ; 2.2.1.2. ERBB2 (HER2) ; 2.2.2. Cetuximab: Anti-EGFR Antibody ; 2.2.2.1. Pre-Clinical Studies ; 2.2.2.2. Preclinical Studies on the Pulmonary Administered of Cetuximab
|
| 505 |
8 |
|
|a 2.2.2.3. Pharmacokinetic 2.2.2.4. Clinical Trials of Cetuximab Combined with Chemotherapy ; 2.2.2.4.1. Phase I/II ; 2.2.2.4.1.1. First Line Therapy ; 2.2.2.4.1.2. Second Line Therapy ; 2.2.2.4.1.3. Bronchioloalveolar Carcinoma ; 2.2.2.4.2. Phase III ; 2.2.2.4.3. Cetuximab and Other Targeted Therapies ; 2.2.2.4.3.1. Anti-EGFR Tyrosine Kinase Inhibitor ; 2.2.2.4.3.2. Bortezomib ; 2.2.2.4.4. Cetuximab and Radiotherapy ; 2.2.2.4.5. Cetuximab and Predictive Markers ; 2.2.3. Anti-EGFR: Matuzumab ; 2.2.4. Anti-EGFR: Nimotuzumab ; 2.2.5. Anti-EGFR: Panitumumab; 2.2.6. Anti-EGFR: Necitumumab
|
| 590 |
|
|
|a eBooks on EBSCOhost
|b EBSCO eBook Subscription Academic Collection - Worldwide
|
| 650 |
|
0 |
|a Lungs
|x Cancer.
|
| 650 |
|
2 |
|a Lung Neoplasms
|x diagnosis
|
| 650 |
|
2 |
|a Lung Neoplasms
|x therapy
|
| 650 |
|
2 |
|a Lung Neoplasms
|
| 650 |
|
6 |
|a Poumons
|x Cancer.
|
| 650 |
|
7 |
|a HEALTH & FITNESS
|x Diseases
|x General.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Clinical Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Diseases.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Evidence-Based Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Internal Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a Lungs
|x Cancer.
|2 fast
|0 (OCoLC)fst01003756
|
| 700 |
1 |
|
|a Hawkins, Andrea
|c (Editor),
|e editor.
|
| 776 |
0 |
8 |
|i Print version:
|t Encyclopedia of lung cancer.
|d New York : Nova Biomedical, [2015]
|z 1634834712
|w (DLC) 2015945689
|
| 830 |
|
0 |
|a Cancer etiology, diagnosis, and treatments.
|
| 856 |
4 |
0 |
|u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1084512
|z Texto completo
|
| 938 |
|
|
|a ProQuest Ebook Central
|b EBLB
|n EBL4189049
|
| 938 |
|
|
|a EBSCOhost
|b EBSC
|n 1084512
|
| 938 |
|
|
|a YBP Library Services
|b YANK
|n 12536673
|
| 994 |
|
|
|a 92
|b IZTAP
|
